{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:13:46Z","timestamp":1780463626283,"version":"3.54.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T00:00:00Z","timestamp":1588896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006419","name":"EuroQol Research Foundation","doi-asserted-by":"publisher","award":["2015280"],"award-info":[{"award-number":["2015280"]}],"id":[{"id":"10.13039\/501100006419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jval.2020.04.1825","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T18:14:28Z","timestamp":1594664068000},"page":"953-968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["EQ-5D\u2013Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review"],"prefix":"10.1016","volume":"23","author":[{"given":"Dominik","family":"Golicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Ja\u015bkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"M\u0142y\u0144czak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Dobrowolska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"And\u017celika","family":"Gawro\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilian","family":"Snarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malwina","family":"Ho\u0142ownia-Voloskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Jakubczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Niewada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jval.2020.04.1825_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jval.2018.01.003","article-title":"Time to entry for new cancer medicines: from European Union-wide marketing authorization to patient access in Belgium, Estonia, Scotland, and Sweden","volume":"21","author":"Ferrario","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.04.1825_bib3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jval.2016.02.016","article-title":"A\u00a0tale of two thresholds: a framework for prioritization within the Cancer Drugs Fund","volume":"19","author":"Leigh","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.04.1825_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/11584210-000000000-00000","article-title":"Advances in cancer therapeutics and patient access to new drugs","volume":"29","author":"Dranitsaris","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1825_bib5","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jval.2020.04.1825_bib6","series-title":"Measuring and Valuing Health Benefits for Economic Evaluation","author":"Brazier","year":"2007"},{"key":"10.1016\/j.jval.2020.04.1825_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0272989X14543107","article-title":"Comparing and explaining differences in the magnitude, content, and sensitivity of utilities predicted by the EQ-5D, SF-6D, HUI 3, 15D, QWB, and AQoL-8D multiattribute utility instruments","volume":"35","author":"Richardson","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.04.1825_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.jval.2020.04.1825_bib9","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib10","series-title":"EQ-5D-3L User Guide (Version 6.0)","year":"2018"},{"issue":"7","key":"10.1016\/j.jval.2020.04.1825_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"suppl 1","key":"10.1016\/j.jval.2020.04.1825_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s40273-017-0547-8","article-title":"The identification, review and synthesis of health state utility values from the literature","volume":"35","author":"Ara","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1825_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","article-title":"Identification, review, and use of health state utilities in cost-effectiveness models: An ISPOR Good Practices for Outcomes Research Task Force Report","volume":"22","author":"Brazier","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.04.1825_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jval.2020.04.1825_bib15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bbmt.2016.03.015","article-title":"Decision analysis of postremission therapy in cytogenetically intermediate-risk acute myeloid leukemia: the impact of FLT3 internal tandem duplication, nucleophosmin, and CCAAT\/enhancer binding protein alpha","volume":"22","author":"Kurosawa","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jval.2020.04.1825_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12324","article-title":"Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study","volume":"93","author":"Leunis","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib17","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2141.1998.00635.x","article-title":"Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia","volume":"100","author":"Uyl-de Groot","year":"1998","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2015.137","article-title":"Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia","volume":"50","author":"Kurosawa","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jval.2020.04.1825_bib19","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8280","article-title":"Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis","volume":"8","author":"Dalziel","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2020.04.1825_bib21","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2020.04.1825_bib22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/cncr.31082","article-title":"Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia\u00a0patients resistant or intolerant to prior therapy","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clinthera.2014.02.008","article-title":"Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand","volume":"36","author":"Kulpeng","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2020.04.1825_bib24","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.20694","article-title":"Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Reed","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","article-title":"Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure","volume":"32","author":"Whiteley","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2020.04.1825_bib26","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2352-3026(17)30168-0","article-title":"Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Chanan-Khan","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40273-015-0332-5","article-title":"Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada","volume":"34","author":"Herring","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1825_bib28","first-page":"2853","article-title":"Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia","volume":"21","author":"Pashos","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib29","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.clinthera.2016.03.009","article-title":"Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer","volume":"38","author":"Pickard","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2020.04.1825_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jogn.2015.12.014","article-title":"Subclinical cardiovascular disease in lymphoma survivors by sex","volume":"45","author":"Reilly","year":"2016","journal-title":"J\u00a0Obstet Gynecol Neonatal Nurs"},{"key":"10.1016\/j.jval.2020.04.1825_bib31","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0959-8049(01)00198-8","volume":"37","author":"van Agthoven","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib32","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/psyg.12205","article-title":"Does cognitive decline decrease health utility value in older adult patients with cancer?","volume":"17","author":"Akechi","year":"2017","journal-title":"Psychogeriatrics"},{"key":"10.1016\/j.jval.2020.04.1825_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-016-0768-2","article-title":"Health-related quality of life and psychological distress among cancer survivors in Southeast Asia: results from a longitudinal study in eight low- and middle-income countries","volume":"15","author":"Kimman","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.jval.2020.04.1825_bib34","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.3109\/10428194.2010.513749","article-title":"Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy","volume":"51","author":"Brandt","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2020.04.1825_bib35","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/0959-8049(96)00142-6","article-title":"Treatment costs in Hodgkin\u2019s disease: a cost-utility analysis","volume":"32A","author":"Norum","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib36","first-page":"787","article-title":"Quality of life (QoL) measurement in economic analysis in cancer: a comparison of the EuroQol questionnaire, a simple QoL-scale and the global QoL measure of the EORTC QLQ-C30","volume":"3","author":"Norum","year":"1996","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jval.2020.04.1825_bib37","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1200\/JCO.2003.01.076","article-title":"CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma","volume":"21","author":"Doorduijn","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2020.04.1825_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0609.2005.00438.x","article-title":"Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy","volume":"75","author":"Doorduijn","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40258-018-0401-y","article-title":"Cost-effectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance versus bendamustine alone in treatment of patients with rituximab-refractory follicular lymphoma in Norway","volume":"16","author":"Haukaas","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.jval.2020.04.1825_bib40","first-page":"463","article-title":"Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL)","volume":"16","author":"Uyl-de Groot","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jval.2020.04.1825_bib41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","article-title":"Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin's lymphoma: results of a prospective randomized controlled trial","volume":"88","author":"Witzens-Harig","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib42","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s11136-012-0220-9","article-title":"An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences","volume":"22","author":"Crott","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0272989X11427761","article-title":"Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D","volume":"32","author":"Versteegh","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.04.1825_bib44","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1080\/10428194.2017.1416364","volume":"59","author":"Cramer","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2020.04.1825_bib45","first-page":"9","article-title":"Cost-effectiveness of rituximab in maintenance treatment of refractory or relapsing follicular non-Hodgkin lymphoma","volume":"9","author":"Berto","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1825_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00277-017-3147-y","article-title":"SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma","volume":"97","author":"Fargier","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib47","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1080\/10428194.2017.1326034","article-title":"Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus","volume":"58","author":"Hess","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2020.04.1825_bib48","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib49","first-page":"599","article-title":"Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey","volume":"21","author":"Acaster","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib50","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/bmt.2012.257","article-title":"In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden","volume":"48","author":"Blijlevens","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jval.2020.04.1825_bib51","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.spinee.2015.09.031","article-title":"Pathologic sternal involvement is a potential risk factor for severe sagittal plane deformity in multiple myeloma with concomitant thoracic fractures","volume":"15","author":"Butler","year":"2015","journal-title":"Spine J"},{"key":"10.1016\/j.jval.2020.04.1825_bib52","first-page":"454","article-title":"Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective","volume":"15","author":"Delea","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib53","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2020.04.1825_bib54","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0272989X15575285","article-title":"Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis","volume":"35","author":"Kharroubi","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.04.1825_bib55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s12885-016-2495-7","article-title":"Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing","volume":"16","author":"Malhotra","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ejp.1139","article-title":"The contribution of pain in determining the health status of cancer patients with bone metastases: a secondary analysis of data from three Phase III registration trials","volume":"22","author":"Mendoza","year":"2018","journal-title":"Eur J Pain"},{"key":"10.1016\/j.jval.2020.04.1825_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-12-35","article-title":"Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma","volume":"12","author":"Proskorovsky","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2020.04.1825_bib58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib59","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jval.2012.08.2201","article-title":"Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer","volume":"15","author":"Rowen","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.04.1825_bib60","series-title":"Intensive Therapy in Multiple Myeloma [thesis]","author":"Segeren","year":"2002"},{"key":"10.1016\/j.jval.2020.04.1825_bib61","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3324\/haematol.2014.112557","article-title":"Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"100","author":"Song","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2020.04.1825_bib62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2004.00346.x","article-title":"Health related quality of life in patients with multiple myeloma undergoing a double transplantation","volume":"74","author":"Uyl-de Groot","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib63","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ejca.2004.01.019","volume":"40","author":"van Agthoven","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib64","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","article-title":"Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 Randomized Phase III Trial","volume":"15","author":"Weisel","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jval.2020.04.1825_bib65","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1177\/0272989X15587497","article-title":"Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L","volume":"35","author":"Young","year":"2015","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.04.1825_bib66","first-page":"136","article-title":"Quality of life and physicians' perception in myelodysplastic syndromes","volume":"2","author":"Oliva","year":"2012","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib67","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41375-018-0089-x","article-title":"Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study","volume":"32","author":"Stauder","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2020.04.1825_bib68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1477-7525-7-81","article-title":"Valuation of transfusion-free living in MDS: results of health utility interviews with patients","volume":"7","author":"Szende","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"suppl 1","key":"10.1016\/j.jval.2020.04.1825_bib69","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10198-016-0790-5","article-title":"Social\/economic costs and health-related quality of life in patients with histiocytosis in Europe","volume":"17","author":"Iskrov","year":"2016","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib70","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11136-014-0828-z","article-title":"The relationship between economic characteristics and health-related quality of life in newly diagnosed cancer patients in Southeast Asia: results from an observational study","volume":"24","author":"Kimman","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40271-016-0190-z","article-title":"EQ-5D health utility scores: data from a comprehensive Canadian cancer centre","volume":"10","author":"Naik","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.jval.2020.04.1825_bib72","first-page":"238","article-title":"Global quality of life in patients who have undergone the hematopoietic stem cell transplantation: finding from transversal and retrospective study","volume":"27","author":"Slovacek","year":"2005","journal-title":"Exp Oncol"},{"key":"10.1016\/j.jval.2020.04.1825_bib73","first-page":"949","volume":"145","author":"Slov\u00e1cek","year":"2006","journal-title":"Cas Lek Cesk"},{"key":"10.1016\/j.jval.2020.04.1825_bib74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.14712\/18059694.2017.67","article-title":"Quality of life in adult patients treated with peripheral blood progenitor cell transplantation: the effect of selected psychosocial, demographics and health aspects on quality of life: a retrospective analysis","volume":"50","author":"Slovacek","year":"2007","journal-title":"Acta Medica (Hradec Kralove)"},{"key":"10.1016\/j.jval.2020.04.1825_bib75","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1507-1367(10)60062-4","article-title":"Health-related quality of life in acute myeloid leukaemia and multiple myeloma survivors undergoing autologous progenitor stem cell transplantation: a retrospective analysis","volume":"12","author":"Slovacek","year":"2007","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.jval.2020.04.1825_bib76","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1507-1367(10)60046-6","article-title":"Quality of life in patients with multiple myeloma and malignant lymphoma undergoing autologous progenitor stem cell transplantation: the effect of selected psychosocial and health aspects on quality of life: a retrospective analysis","volume":"12","author":"Slovacek","year":"2007","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.jval.2020.04.1825_bib77","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00134-012-2791-x","article-title":"Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study","volume":"39","author":"Oeyen","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jval.2020.04.1825_bib78","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/02841860802120028","article-title":"Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden","volume":"47","author":"Kasteng","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jval.2020.04.1825_bib79","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1825_bib80","doi-asserted-by":"crossref","first-page":"e392","DOI":"10.3747\/co.19.1004","article-title":"Cost-effectiveness of zoledronic acid compared with clodronate in multiple myeloma","volume":"19","author":"Delea","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jval.2020.04.1825_bib81","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00019053-200523050-00010","article-title":"Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia","volume":"23","author":"Dalziel","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1825_bib82","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bjh.13450","article-title":"Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry","volume":"170","author":"de Swart","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2020.04.1825_bib84","first-page":"10","article-title":"Surgery for vertebral involvement in Multiple Myeloma","volume":"62","author":"Donnarumma","year":"2018","journal-title":"J\u00a0Neurosurg Sci"},{"key":"10.1016\/j.jval.2020.04.1825_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002317","article-title":"Patient-reported outcomes of cancer survivors in England 1-5 years after diagnosis: a cross-sectional survey","volume":"3","author":"Glaser","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jval.2020.04.1825_bib86","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","article-title":"Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes","volume":"121","author":"Jansen","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib87","first-page":"3171","article-title":"Patient-reported outcomes in cancer survivors: a population-wide cross-sectional study","volume":"25","author":"Jefford","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib88","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/cncr.24883","article-title":"Evaluating the ability to detect change of health-related quality of life in children with Hodgkin disease","volume":"116","author":"Klaassen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2020.04.1825_bib89","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","article-title":"Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma","volume":"87","author":"Kvam","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib90","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/sj.bmt.1701142","article-title":"Prospective economic evaluation accompanying a trial of GM-CSF\/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkins and non-Hodgkins-lymphoma (Structured abstract)","volume":"21","author":"Schulman","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jval.2020.04.1825_bib91","first-page":"57","article-title":"Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: results of the BEN-001 study","volume":"89","author":"Stadnik","year":"2017","journal-title":"Ter Arkh"},{"key":"10.1016\/j.jval.2020.04.1825_bib92","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1302\/0301-620X.98B9.37786","article-title":"The relationship between spinopelvic measurements and patient-reported outcome scores in patients with multiple myeloma of the spine","volume":"98-B","author":"Yu","year":"2016","journal-title":"Bone Joint J"},{"key":"10.1016\/j.jval.2020.04.1825_bib93","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2020.04.1825_bib94","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2020.04.1825_bib95","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jval.2011.06.005","article-title":"Estimating population-based values for EQ-5D health states in Thailand","volume":"14","author":"Tongsiri","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.04.1825_bib96","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s10198-004-0264-z","article-title":"Validating the EQ-5D with time trade off for the German population","volume":"6","author":"Greiner","year":"2005","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib97","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/hec.673","article-title":"Estimating an EQ-5D population value set: the case of Japan","volume":"11","author":"Tsuchiya","year":"2002","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib98","series-title":"Estimating a parametric relation between health description and health valuation using the EuroQol instrument","first-page":"45","author":"Van Hout","year":"1991"},{"key":"10.1016\/j.jval.2020.04.1825_bib99","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10198-009-0167-0","article-title":"A\u00a0social preference valuations set for EQ-5D health states in Flanders, Belgium","volume":"11","author":"Cleemput","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib100","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hec.1124","article-title":"The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies","volume":"15","author":"Lamers","year":"2006","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib101","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","article-title":"A\u00a0single European currency for EQ-5D health states. Results from a six-country study","volume":"4","author":"Greiner","year":"2003","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib102","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: An EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib103","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","article-title":"German Value Set for the EQ-5D-5L","volume":"36","author":"Ludwig","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.04.1825_bib104","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.04.1825_bib105","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s11136-015-1212-3","article-title":"Health state utility instruments compared: inquiring into nonlinearity across EQ-5D-5L, SF-6D, HUI-3 and 15D","volume":"25","author":"Gamst-Klaussen","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib106","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.psychres.2019.02.077","article-title":"A\u00a0comparison of the reliability and validity of SF-6D, EQ-5D and HUI3 utility measures in patients with schizophrenia and patients with depression in Singapore","volume":"274","author":"Abdin","year":"2019","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib107","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/0272989X15578127","article-title":"Mapping between 6 Multiattribute Utility Instruments","volume":"36","author":"Chen","year":"2016","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.04.1825_bib108","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/hec.3871","article-title":"Frequentist and Bayesian meta-regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data","volume":"28","author":"Hatswell","year":"2019","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2020.04.1825_bib109","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s11136-010-9648-y","article-title":"Development of the EQ-5D-Y: a child-friendly version of the EQ-5D","volume":"19","author":"Wille","year":"2010","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib110","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jval.2018.05.002","article-title":"Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) health states: the impact of wording and perspective","volume":"21","author":"Kreimeier","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.04.1825_bib111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0272989X13497263","article-title":"Health status utilities in pediatrics: a systematic review of acute lymphoblastic leukemia","volume":"34","author":"van Litsenburg","year":"2014","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.04.1825_bib112","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00005650-199607000-00004","article-title":"Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2","volume":"34","author":"Torrance","year":"1996","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2020.04.1825_bib113","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","article-title":"Multiattribute and single-attribute utility functions for the health utilities index mark 3 system","volume":"40","author":"Feeny","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2020.04.1825_bib114","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ctrv.2018.07.005","article-title":"Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia","volume":"69","author":"Bosshard","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jval.2020.04.1825_bib115","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.leukres.2018.06.006","article-title":"A\u00a0systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia","volume":"70","author":"Bryant","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib116","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.critrevonc.2015.07.012","article-title":"Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned?","volume":"96","author":"Cannella","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40487-016-0039-6","article-title":"Health-related quality of life of patients with acute myeloid leukemia: a systematic literature review","volume":"5","author":"Korol","year":"2017","journal-title":"Oncol Ther"},{"key":"10.1016\/j.jval.2020.04.1825_bib118","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.21503","article-title":"Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review","volume":"84","author":"Pinchon","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jval.2020.04.1825_bib119","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/NCC.0000000000000327","article-title":"A\u00a0systematic review of psychometric properties of health-related quality-of-life and symptom instruments in adult acute leukemia survivors","volume":"39","author":"Bryant","year":"2016","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.jval.2020.04.1825_bib120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/CEOR.S153286","article-title":"Systematic review of health state utility\u00a0values for acute myeloid leukemia","volume":"10","author":"Forsythe","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib121","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1080\/03007995.2018.1474091","article-title":"Systematic literature review of health-related quality of life among aggressive non-Hodgkin lymphoma survivors","volume":"34","author":"Lin","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jval.2020.04.1825_bib122","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/CEOR.S187409","article-title":"Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review","volume":"11","author":"Forsythe","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jval.2020.04.1825_bib123","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","article-title":"Health utilities using the EQ-5D in studies of cancer","volume":"25","author":"Pickard","year":"2007","journal-title":"Pharmacoeconomics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520320568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520320568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:59:29Z","timestamp":1778590769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520320568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1098301520320568"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.04.1825","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EQ-5D\u2013Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.04.1825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}